Oppenheimer & CO Inc Neurocrine Biosciences Inc Transaction History

Oppenheimer & CO Inc

  • $7.83 Billion
  • Q3 2025

A detailed history of Oppenheimer & CO Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Oppenheimer & CO Inc holds 41,023 shares of NBIX stock, worth $5.94 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
41,023
Previous 40,398 1.55%
Holding current value
$5.94 Million
Previous $5.08 Million 13.41%
% of portfolio
0.07%
Previous 0.07%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 05, 2025
BUY
$123.98 - $146.67 $77,487 - $91,668
625 Added 1.55%
41,023 $5.76 Million
Q2 2025

Jul 31, 2025
BUY
$87.54 - $128.18 $1.84 Million - $2.69 Million
21,010 Added 108.37%
40,398 $5.08 Million
Q1 2025

Apr 22, 2025
BUY
$107.22 - $153.29 $47,927 - $68,520
447 Added 2.36%
19,388 $2.14 Million
Q4 2024

Feb 04, 2025
SELL
$111.62 - $139.44 $38,843 - $48,525
-348 Reduced 1.8%
18,941 $2.59 Million
Q3 2024

Nov 05, 2024
BUY
$114.58 - $153.15 $235,003 - $314,110
2,051 Added 11.9%
19,289 $2.22 Million
Q2 2024

Aug 07, 2024
BUY
$130.86 - $143.19 $37,033 - $40,522
283 Added 1.67%
17,238 $2.37 Million
Q1 2024

May 06, 2024
SELL
$130.4 - $143.74 $27,905 - $30,760
-214 Reduced 1.25%
16,955 $2.34 Million
Q4 2023

Feb 13, 2024
BUY
$106.07 - $132.76 $26,411 - $33,057
249 Added 1.47%
17,169 $2.26 Million
Q3 2023

Nov 07, 2023
BUY
$94.02 - $117.1 $41,086 - $51,172
437 Added 2.65%
16,920 $1.9 Million
Q2 2023

Aug 02, 2023
BUY
$89.53 - $104.87 $2,238 - $2,621
25 Added 0.15%
16,483 $1.55 Million
Q1 2023

May 10, 2023
SELL
$94.11 - $123.02 $333,055 - $435,367
-3,539 Reduced 17.7%
16,458 $1.67 Million
Q4 2022

Feb 07, 2023
BUY
$106.72 - $127.06 $157,198 - $187,159
1,473 Added 7.95%
19,997 $2.39 Million
Q3 2022

Nov 14, 2022
BUY
$92.03 - $107.81 $575,831 - $674,567
6,257 Added 51.01%
18,524 $1.97 Million
Q2 2022

Aug 08, 2022
BUY
$75.79 - $100.07 $10,989 - $14,510
145 Added 1.2%
12,267 $1.2 Million
Q1 2022

May 12, 2022
SELL
$72.45 - $94.81 $11,881 - $15,548
-164 Reduced 1.33%
12,122 $1.14 Million
Q4 2021

Feb 02, 2022
BUY
$79.65 - $106.22 $511,591 - $682,251
6,423 Added 109.55%
12,286 $1.05 Million
Q3 2021

Nov 12, 2021
BUY
$86.18 - $99.03 $15,770 - $18,122
183 Added 3.22%
5,863 $562,000
Q2 2021

Aug 03, 2021
BUY
$89.43 - $102.27 $159,274 - $182,142
1,781 Added 45.68%
5,680 $553,000
Q1 2021

May 10, 2021
SELL
$87.57 - $119.4 $1,401 - $1,910
-16 Reduced 0.41%
3,899 $379,000
Q4 2020

Feb 11, 2021
BUY
$86.91 - $108.33 $11,124 - $13,866
128 Added 3.38%
3,915 $375,000
Q3 2020

Nov 13, 2020
BUY
$96.16 - $135.15 $73,850 - $103,795
768 Added 25.44%
3,787 $364,000
Q2 2020

Aug 11, 2020
SELL
$85.09 - $130.36 $24,165 - $37,022
-284 Reduced 8.6%
3,019 $369,000
Q1 2020

May 08, 2020
SELL
$75.11 - $113.76 $245,159 - $371,312
-3,264 Reduced 49.7%
3,303 $286,000
Q4 2019

Feb 07, 2020
BUY
$86.8 - $118.57 $52,340 - $71,497
603 Added 10.11%
6,567 $706,000
Q3 2019

Oct 31, 2019
BUY
$83.82 - $101.5 $274,091 - $331,905
3,270 Added 121.38%
5,964 $537,000
Q2 2019

Aug 09, 2019
SELL
$72.24 - $91.27 $303,046 - $382,877
-4,195 Reduced 60.89%
2,694 $227,000
Q1 2019

Apr 24, 2019
BUY
$69.31 - $91.53 $122,886 - $162,282
1,773 Added 34.66%
6,889 $607,000
Q4 2018

Jan 29, 2019
SELL
$68.32 - $124.36 $90,797 - $165,274
-1,329 Reduced 20.62%
5,116 $365,000
Q3 2018

Oct 26, 2018
BUY
$98.88 - $125.85 $303,363 - $386,107
3,068 Added 90.85%
6,445 $792,000
Q2 2018

Aug 10, 2018
SELL
$75.3 - $105.99 $11,972 - $16,852
-159 Reduced 4.5%
3,377 $332,000
Q1 2018

May 01, 2018
BUY
$75.88 - $92.43 $268,311 - $326,832
3,536 New
3,536 $293,000

Others Institutions Holding NBIX

# of Institutions
730
Shares Held
102M
Call Options Held
230K
Put Options Held
477K
View Full List

About NEUROCRINE BIOSCIENCES INC

NBIX Quotes by TradingView
  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13.9B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Oppenheimer & CO Inc Portfolio

Follow Oppenheimer & CO Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer & CO Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email